Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MIF | P14174 | 3/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143624 | 1.00 | ESR1 (0.54) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL1143625 | 1.00 | ESR1 (0.54) | ESR1ESR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL6383646 | 0.98 | ESR1 (0.53) | ESR1ESR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL1584177 | 0.98 | ESR1 (0.53) | ESR1ESR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL2505671 | 0.98 | ESR1 (0.53) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL7252180 | 0.92 | KMT2A (0.48) | ESR1ESR2CA12CA1CA2 | |
| Cadaverine Tartrate SCHEMBL32662847 | 0.90 | ESR1 (0.46) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL8252300 | 0.84 | L3MBTL1 (0.45) | ESR1ESR2KMT2AMT-CO2ALDH1A1 | |
| SCHEMBL9620180 | 0.84 | SLC6A3 (0.47) | ESR1ESR2KMT2AMT-CO2ALDH1A1 | |
| SCHEMBL8058922 | 0.84 | L3MBTL1 (0.45) | ESR1ESR2KMT2AMT-CO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| CN-121574765-A | Lubricating grease composition for roller bearing and preparation method thereof | 廊坊市兰春润滑脂有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-12310945-B2 | Cyclohexylglycine derivatives as selective cytotoxic agents | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240252466-A1 | CYCLOHEXYLGYCINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC | 2024-08-01 | — | — | US | disclosed |
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2023-12-07 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4237417-A1 | INTERLEUKIN-17 INHIBITORS | Novartis AG (CH) | 2023-09-06 | — | — | EP | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-5397700-A | Method of producing products with a bilayer pellet containing a coimmobilized enzyme system that maintains a ph difference | UNIVERSITY OF TOLEDO (US) | 1995-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | IL17A, IL2, IL18 | ESR1 2643/4885ESR2 975/4885CA12 4169/4885 |
| US-12310945-B2 | Cyclohexylglycine derivatives as selective cytotoxic agents | CD4, GZMB, GAA | ESR1 4379/4885ESR2 4351/4885CA12 3958/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ESR1 1673/4885ESR2 684/4885CA12 4365/4885 |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | ESR1 4808/4885ESR2 4687/4885CA12 1863/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | ESR1 4449/4885ESR2 3356/4885CA12 376/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | ESR1 4445/4885ESR2 3046/4885CA12 373/4885 |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | ESR1 3556/4885ESR2 2644/4885CA12 461/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | ESR1 3040/4885ESR2 2859/4885CA12 4369/4885 |
| US-20240252466-A1 | CYCLOHEXYLGYCINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | GZMB, CD4, CD74 | ESR1 4250/4885ESR2 4220/4885CA12 4706/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ESR1 4449/4885ESR2 3356/4885CA12 376/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | ESR1 3556/4885ESR2 2644/4885CA12 461/4885 |
| US-12600728-B2 | Interleukin-17 inhibitors | IL17A, IL2, IL1B | ESR1 3656/4885ESR2 3214/4885CA12 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.